WO1999061071A3 - Techniques permettant de marquer des vecteurs a base d'acides nucleiques avec des oligonucleotides formant des triplex et d'analyser la distribution desdits vecteurs - Google Patents
Techniques permettant de marquer des vecteurs a base d'acides nucleiques avec des oligonucleotides formant des triplex et d'analyser la distribution desdits vecteurs Download PDFInfo
- Publication number
- WO1999061071A3 WO1999061071A3 PCT/US1999/011511 US9911511W WO9961071A3 WO 1999061071 A3 WO1999061071 A3 WO 1999061071A3 US 9911511 W US9911511 W US 9911511W WO 9961071 A3 WO9961071 A3 WO 9961071A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- labeled
- nucleic acid
- imaging
- tfos
- triplex
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 2
- 238000001727 in vivo Methods 0.000 title abstract 2
- 238000003556 assay Methods 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 abstract 8
- 102000039446 nucleic acids Human genes 0.000 abstract 8
- 150000007523 nucleic acids Chemical class 0.000 abstract 8
- 238000003384 imaging method Methods 0.000 abstract 4
- 238000000338 in vitro Methods 0.000 abstract 2
- 231100001074 DNA strand break Toxicity 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000002716 delivery method Methods 0.000 abstract 1
- 210000003527 eukaryotic cell Anatomy 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 239000012216 imaging agent Substances 0.000 abstract 1
- 238000002595 magnetic resonance imaging Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002600 positron emission tomography Methods 0.000 abstract 1
- 238000002603 single-photon emission computed tomography Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6839—Triple helix formation or other higher order conformations in hybridisation assays
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Optics & Photonics (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU43124/99A AU4312499A (en) | 1998-05-26 | 1999-05-26 | Methods for labeling nucleic acid vectors with triplex-forming oligonucleotides and monitoring vector distribution in vivo |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8670498P | 1998-05-26 | 1998-05-26 | |
US60/086,704 | 1998-05-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999061071A2 WO1999061071A2 (fr) | 1999-12-02 |
WO1999061071A3 true WO1999061071A3 (fr) | 2000-06-22 |
Family
ID=22200322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/011511 WO1999061071A2 (fr) | 1998-05-26 | 1999-05-26 | Techniques permettant de marquer des vecteurs a base d'acides nucleiques avec des oligonucleotides formant des triplex et d'analyser la distribution desdits vecteurs |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU4312499A (fr) |
WO (1) | WO1999061071A2 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001286268B2 (en) * | 2000-09-19 | 2006-04-27 | Takara Bio Inc. | Method of forming complex |
MX2020013183A (es) | 2018-06-07 | 2021-04-13 | Amgen Inc | Ensayo de deteccion de conjugados de proteina-polinucleotido. |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992011390A1 (fr) * | 1990-12-17 | 1992-07-09 | Idexx Laboratories, Inc. | Detection de sequences d'acide nucleique par la formation d'une triple helice de l'adn |
US5789155A (en) * | 1987-10-30 | 1998-08-04 | California Institute Of Technology | Process for identifying nucleic acids and triple helices formed thereby |
WO1998037231A2 (fr) * | 1997-02-22 | 1998-08-27 | Ruprecht-Karls-Universität Heidelberg | Marquage d'acides nucleiques avec des melanges de sondes speciales |
WO1999024622A1 (fr) * | 1997-11-10 | 1999-05-20 | Princeton University | Hybridation in-situ triplex |
-
1999
- 1999-05-26 AU AU43124/99A patent/AU4312499A/en not_active Abandoned
- 1999-05-26 WO PCT/US1999/011511 patent/WO1999061071A2/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5789155A (en) * | 1987-10-30 | 1998-08-04 | California Institute Of Technology | Process for identifying nucleic acids and triple helices formed thereby |
WO1992011390A1 (fr) * | 1990-12-17 | 1992-07-09 | Idexx Laboratories, Inc. | Detection de sequences d'acide nucleique par la formation d'une triple helice de l'adn |
WO1998037231A2 (fr) * | 1997-02-22 | 1998-08-27 | Ruprecht-Karls-Universität Heidelberg | Marquage d'acides nucleiques avec des melanges de sondes speciales |
WO1999024622A1 (fr) * | 1997-11-10 | 1999-05-20 | Princeton University | Hybridation in-situ triplex |
Non-Patent Citations (6)
Title |
---|
DEBIN A ET AL: "Investigation of the formation and intracellular stability of purine.(purine/pyrimidine) triplexes.", NUCLEIC ACIDS RESEARCH, (1997 MAY 15) 25 (10) 1965-74., XP002121050 * |
DEWANJEE M. K. ET AL.: "Noninvasive Imaging of c-myc Oncogene Messeger RNA with Indium-111-Antisense Probes in a Mammary Tumor-Bearing Mouse Model", THE JOURNAL OF NUCLEAR MEDICINE, vol. 35, no. 6, 1994, pages 1054 - 1063, XP002121053 * |
EBBINGHAUS S W ET AL: "EFFICIENT DELIVERY OF TRIPLEX FORMING OLIGONUCLEOTIDES TO TUMOR CELLS BY ADENOVIRUS-POLYLYSINE COMPLEXES", GENE THERAPY, vol. 3, no. 4, 1 April 1996 (1996-04-01), pages 287 - 297, XP000600781 * |
PANUTYN I. G. ET AL.: "Radioprobing of DNA: distribution of DNA breaks produced by decay of 125-I incorporated into a triplex-forming oligonucleotide correlates with geometry of the triplex.", NUCLEIC ACID RESEARCH, vol. 25, no. 4, 1997, pages 883- - 887, XP002121051 * |
PANYUTIN I. G. ET AL.: "Sequence specific DNA double-strand breaks induced by triplex forming I labeled oligonucleotides", NUCLEIC ACID RESEARCH, vol. 22, no. 23, 1994, pages 4979 - 4982, XP002121052 * |
SEDELNIKOVA O.A. ET AL: "The stability of DNA triplexes inside cells as studied by iodine-125 radioprinting.", NUCLEIC ACIDS RESEARCH, (1 OCT 1999) 27/19 (3844-3850)., XP002121049 * |
Also Published As
Publication number | Publication date |
---|---|
AU4312499A (en) | 1999-12-13 |
WO1999061071A2 (fr) | 1999-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Louie et al. | In vivo visualization of gene expression using magnetic resonance imaging | |
Gambhir et al. | Imaging gene expression: principles and assays | |
Gambhir et al. | Assays for noninvasive imaging of reporter gene expression | |
Acton et al. | Imaging reporter genes for cell tracking with PET and SPECT | |
Tavitian | In vivo imaging with oligonucleotides for diagnosis and drug development | |
Wu et al. | Molecular imaging of cardiovascular gene products | |
KR20170067820A (ko) | 핵 유전자 산출량의 표적화 증강 | |
Keliris et al. | A smart 19F and 1H MRI probe with self‐immolative linker as a versatile tool for detection of enzymes | |
AU2001249297A1 (en) | Whole-body optical imaging of gene expression and uses thereof | |
WO2001071009A2 (fr) | Imagerie optique corps entier de l'expression genique et utilisations correspondantes | |
CN105734159B (zh) | 食管鳞癌的分子标记物 | |
Lee et al. | Magnetic resonance reporter gene imaging | |
Piwnica‐Worms et al. | Technoreview: Molecular imaging of host–pathogen interactions in intact small animals | |
Chakrabarti et al. | Radiohybridization PET imaging of KRAS G12D mRNA expression in human pancreas cancer xenografts with [64Cu] DO3A-peptide nucleic acid-peptide nanoparticles | |
US8236572B2 (en) | Chemical exchange saturation transfer based MRI using reporter genes and MRI methods related thereto | |
Lok | Picture perfect | |
Bhaumik et al. | Molecular imaging of gene expression in living subjects by spliceosome-mediated RNA trans-splicing | |
Qiao et al. | Death and proliferation time course of stem cells transplanted in the myocardium | |
WO1999061071A3 (fr) | Techniques permettant de marquer des vecteurs a base d'acides nucleiques avec des oligonucleotides formant des triplex et d'analyser la distribution desdits vecteurs | |
Lee et al. | L-DNA linear duplex: An efficient drug delivery carrier with a simple structure | |
Shen et al. | Antisense peptide nucleic acid-functionalized cationic nanocomplex for in vivo mRNA detection | |
Phelps et al. | Quantitative assay development for PET | |
Hauck et al. | Whole animal in vivo imaging after transient, nonviral gene delivery to the rat central nervous system | |
Rodriguez-Porcel et al. | Molecular imaging of stem cells | |
CN102533834A (zh) | 一种在体无创监测microRNA表达的双模态成像报告基因的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |